<SEC-DOCUMENT>0001144204-17-050846.txt : 20171002
<SEC-HEADER>0001144204-17-050846.hdr.sgml : 20171002
<ACCEPTANCE-DATETIME>20171002103753
ACCESSION NUMBER:		0001144204-17-050846
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171002
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171002
DATE AS OF CHANGE:		20171002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		171113371

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v476260_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 185.85pt 0pt 200.95pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 185.85pt 0pt 200.95pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 185.85pt 0pt 200.95pt; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 185.85pt 0pt 200.95pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 185.85pt 0pt 200.95pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 78.85pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 188.75pt 0pt 200.8pt; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 214.8pt 0pt 227pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 163.15pt 0pt 178.15pt; text-align: center; text-indent: 0.05pt"><B>CURRENT
REPORT Pursuant to</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 163.15pt 0pt 178.15pt; text-align: center; text-indent: 0.05pt"><B>Section 13 or 15(d) of the Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 163.15pt 0pt 178.15pt; text-align: center; text-indent: 0.05pt"><B>Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 79.55pt 0pt 91.55pt; text-align: center"><B>Date of report (Date
of earliest event reported): October 2, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 151.3pt 0pt 163pt; text-align: center"><B>STAAR Surgical Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 151.3pt 0pt 163pt; text-align: center"><B>(Exact Name of Registrant
as Specified in Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR>
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><U>Delaware</U></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><U>0-11634</U></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><U>95-3797439</U></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">(State or Other Jurisdiction</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">of Incorporation)</P></TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">(Commission</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">File Number)</P></TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">(I.R.S. Employer</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR>
    <TD STYLE="width: 66%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><U>1911 Walker
    Ave., Monrovia, California</U></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><U>91016</U></TD>
    </TR>
<TR>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-align: center">(Address of Principal Executive Offices)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">(Zip Code)</TD></TR>
<TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">Registrant&rsquo;s
    Telephone Number, Including Area Code <U>626-303-7902</U></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center">Not Applicable</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>(Former Name or Former Address, if Changed Since
Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I>
General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 7.01 Regulation FD Disclosure. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">STAAR Surgical Company issued a press release
regarding the appointment of Dr. Scott Barnes as Chief Medical Officer. A copy of the press release is furnished as Exhibit 99.1
to this Report, and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be
&ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this Current Report, regardless of any general incorporation language in the filing</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 9.01</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Statements and Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 2%; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 88%">(d) Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><U>Exhibit No.</U></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><U>Description</U></TD></TR>
<TR>
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in"><A HREF="v476260_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="v476260_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release dated October 2, 2017.</A></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STAAR Surgical Company&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2, 2017</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 82%; font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Caren Mason</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v476260_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="color: #365F91; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="color: #365F91; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="color: Black"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="color: #365F91; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="color: #365F91; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 50.25pt; width: 240.75pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STAAR Surgical Appoints Scott D. Barnes,
M.D. as Chief Medical Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Distinguished
Ophthalmology Clinician to Serve as Strategic Guide for STAAR&rsquo;s Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&amp; Professional Affairs as well as Product Development
Pathways</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>MONROVIA, CA, October 2, 2017</B>---STAAR
Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems
for the eye, today announced the appointment of Scott D. Barnes M.D. as Chief Medical Officer, a newly created position. Dr. Barnes
will report to Caren Mason, STAAR&rsquo;s President and CEO, will serve on the Company&rsquo;s Executive Management team, and will
provide strategic guidance for STAAR&rsquo;s medical affairs, professional affairs and product development pathways. In addition,
he will lead the Company&rsquo;s Surgeon Training and Certification programs as well as the Company&rsquo;s Surgeon Working Groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Dr. Barnes is joining the Company today
as he travels to Lisbon, Portugal to STAAR&rsquo;s annual <I>Experts Summit </I>with the spotlight on low to moderate diopter usage
of the EVO Visian ICL&trade;. Following the <I>Experts Summit</I>, Dr. Barnes will be speaking at the STAAR Surgical exhibit during
the European Society of Cataract and Refractive Surgeons Meeting where he will provide an update on published, peer reviewed data
on the clinical performance of the ICL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Dr. Barnes is one of the Ophthalmology
industry&rsquo;s thought leaders having authored numerous peer-reviewed journal publications, reviews, chapters and editorials.
In addition, during the course of his career he has given more than 100 presentations and lectures as well as led over 30 ophthalmology
or refractive surgery research projects. He has been awarded <I>Speaker of the Day</I> ten times at industry meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Since 2012, Dr. Barnes has served as
Chief of Ophthalmology Services; Womack Army Medical Center, Fort Bragg, North Carolina. He joined Womack in 2004 as Chief of Ophthalmology
and Refractive Surgery Center and served as a theater ophthalmology consultant in Iraq and Afghanistan during 2005. In 2006, he
returned to Womack as Chief of Refractive Surgery and in 2008 was designated Army Surgeon General A, which is similar to the professor
level in a civilian institution. Dr. Barnes began his medical career in 1986 as a research assistant in the Department of Genetics,
Harvard Medical School/Children&rsquo;s Hospital in Boston and in 1991 became a general surgery intern at William Beaumont Army
Medical Center. His other military appointments included Madigan Army Medical Center, Wilford Hall Medical Center/Brooke Army Medical
Center where he served as a resident in Ophthalmology, and Martin Army Community Hospital where he served as staff Ophthalmologist
and then Chief of Ophthalmology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%; text-align: right">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition to earning his Bachelor
of Arts degree from Wheaton College, and his doctorate degree from Northwestern University Medical School in Chicago, Dr. Barnes&rsquo;
post-doctoral training includes a Cornea Fellowship at the Massachusetts Eye and Ear Infirmary/Harvard Medical School in Boston.
He holds active instructor certification for STAAR&rsquo;s Visian Implantable Collamer Lens (ICL) as well as VISX excimer laser
and Advanced Trauma Life Support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;Dr. Barnes is one of the true
leaders in both ophthalmology and refractive surgery,&rdquo; said Ms. Mason. &ldquo;He comes to STAAR after a distinguished 30-year
career with the military. Our global team has had the pleasure of working with Dr. Barnes over the years as he trained several
refractive surgeons on the use of our ICL during his off-duty leave time. Additionally, he has personally implanted more than 3,000
ICLs in the eyes of our nation&rsquo;s service men and women. Our team looks forward to his insights and contributions as our new
Chief Medical Officer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;As a practicing refractive surgeon,
I have become intimately familiar with the unique and beneficial properties of STAAR&rsquo;s Collamer&reg; material and the Visian
ICL,&rdquo; said Dr. Barnes. &ldquo;I believe STAAR has several pending opportunities to provide ophthalmic products to the marketplace
that offer unique patient benefits and significant growth opportunities. I look forward to helping the Company maximize these growth
opportunities in concert with achieving our mission to provide outstanding surgeon support and patient vision satisfaction.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%; text-align: right">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>About STAAR Surgical</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR, which has been dedicated solely to ophthalmic surgery
for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive
surgery is called an Implantable Collamer&reg; Lens or &quot;ICL&quot;. More than 700,000 Visian ICLs have been implanted to date.
To learn more about the ICL go to: www.discovericl.com. STAAR has approximately 340 full-time equivalent employees and markets
lenses in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and
Monrovia, CA. For more information, please visit the Company's website at www.staar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Safe Harbor</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: future prospects of the Company,
its growth and new product opportunities, and any assumptions underlying any of the foregoing. Important factors that could cause
actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company&rsquo;s
Annual Report on Form 10-K for the year ended December 31, 2016, under the caption &ldquo;Risk Factors&rdquo;, which is on file
with the Securities and Exchange Commission and available in the &ldquo;Investor Information&rdquo; section of the company&rsquo;s
website under the heading &ldquo;SEC Filings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are based on expectations and assumptions as
of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR>
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif">CONTACT:</TD><TD STYLE="width: 2%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 88%; font: bold 10pt Times New Roman, Times, Serif">Investors</TD></TR>
<TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.5in; padding-left: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">EVC Group</TD></TR>
<TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.5in; padding-left: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Brian Moore, 310-579-6199</TD></TR>
<TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.5in; padding-left: 1in"></TD><TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Doug Sherk, 415-652-9100</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%; text-align: right">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 40&3 P$1  (1 0,1 ?_$ +4  0 !! ,  P
M       ) 0<("@(%!@,$"P$!  ,  P$!              $" P0&!P4($
M!@(" 0,"! $'!@\    ! @,$!08 !Q$("2$2$S$402(5"E%A<9&Q,B06\(%"
M([87H<%B5"5UM38G=QB(.7DZ$0 " 0(% @,& @@%!0       0(1 R$Q$@0%
M009180?P<8$B,A.AP9&Q0E)B<B,4T>&"%0@S0R0T%O_:  P# 0 "$0,1 #\
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MZI^3+BE4*< $H_V@Y#T^H<\9QDFZTZ'U=2IC@WT>#_1F<\@D8!03 'IZC_,
MCQ_/P'I@%< 8 P!@# & , 8 P!@# & , 8 ^GKC(''WE]/K^;Z?E, ?QXY$.
M '(U('+) P!@# & , 8 P!R'/'X_Y_Z_IDI5= 5R7%K%@IE0, 991;54!SZ\
M?Y?TY#33HP,@# & , 8 P"@F ! /7DW/' "/TXYYX^GUQ2N0.)E"%_M")?P]
M0'U'^ >GUQ1@Y@//^7'_  #ZX P#@H<"% 1Y]3%*'''J)A  #U$/J(Y*IU=/
M;+WD2:6;IC[+ AR[K^3%'5<_(:>Z^HLK9LQLZ-%3MK<-32T)4I=4P(_HL+')
M>X+):45#@4Y/S-FRGY# JI[B%[SP':3W]N._Y1_:V6K)X2\=35*:<\:UK3#J
M?G/U.]=-MP.]?;G:<8;SF]?VIM)TL3:>"P^:[X+Z:5J\*&(^NO'-VL[42:6R
M>R^QI:G-Y7VNTB6]5>R7Y9DN(K$*RJPN&T/46I@,($14,D9,./[OQZ9V;=]U
M</P-=GP-E7=.#FTM+:\'6KZ]#S[B?1GU"]0+G^Z=][]V^.NTE_4AKOM/I&-5
M&VDJ8U=?# D)HOB6ZGU=!'_$,9<-B/4P)\KBSVQZR:*' /SB6-K!(1 A#?@!
MC'$/XYUG=^H'<MYZ(7(VK3Z07Z_,]:XK_C[Z>[&W&.YA?WMVW@I3FX47[J4%
M%4KCC5XYEZDO';TR21!'_<+5#E  #W*/[,HM_G7/.&6$?Y>><^.^[.X*X;FX
M=LCZ2>GD8Z?]KL2\Y.4G^EXEM+?XJ>GEG26+'TRPTE<X&^)U4KG-I? 82\%$
M&DXM-,E"@(\B!B>N<W;=\]P[>G]17*?O+,^-RGH3Z<\G"7_ANU<>7VW1+W$?
MVT_$]N;4C\U]ZP;3?V.1BA.\9Q3AX:CW] 4.3@G$S\:[0AI=4"AP":WV?R_3
M@W/ ]KV_?VRY33M^Y;,+=JB6I)/RJ_:IY#SG_'WG^ OOE>R-Y.\K:K]MW'8O
MQ6:C"["JHLDI1;PQ=3VW5?R<W:GV]#2?<9F^C7[*0)!!L25BQA9VO2)E"I(L
MMBPX(-D3LS"(!^I()D$@#[U2G((JA\_G>T-M>V_^X\!-7-MFXIU:I\/S/J^G
MWK;R&PY/_P"2]1HN&[C2,-Q-:;LFW1?<C32EXM-OR)X6SQ!XDBX:G*X;N")J
MH.$3IJH+(JD!1)=)5,YR*(JIF Q3%$0,40$,\VH]<H/"4?$_5$)PNQ4[4E*U
M*"DI)UBT_!F!GD\[FN.@W2S;O92*K[:TVNKH04!18*0%<L,\NMRG&-;KZT\=
MJ=-R$'&.9 7;HJ9BJ+)H"D4Q3' P0VHK4S6W%2EI>1J;]88']P-Y/M<3/:_4
M?>Z-J$#_ (GG8J&I#7:1=:E5DH9R#=ZQCZ/1*;+1-;CDU0^-M^M*%6<)@"H^
M\A@4/E-W)I?;>-3>4;,,'4G,\.]Z\R#NV[DU3Y(:.W)0-8-6473]MVQK"1M\
MMMM4=$$L?5Y.FD"K[-I/Z0FHLO,G31707%)+Y5CG5(DM.XT_N.IC/1@X&4_E
MEU3Y"=N:3U[ >.79R6K-K1^SVLK=)I6Y,:2#[7Y:U8&J\:61?P4^FZ$T\X9*
M?"5(IA!/W>[TX';&F&9$-'[=33O[0[T\\/4#L+JSK#N;NO>&VU-QH5)S2F]8
MV-7Y^O*)7:WK4:#&6FQIC$(P33S<P+<I'^-$ /Z\@&4=VD_MNNHWC"S)5538
M?\9G7+SH:E[1QMG[X=@XS9?752C7.+FZV.T(6Z.0M3ANT4J,BTBT*5!NT5&S
M] X'53<%]J9Q Q3 (\:8KZLC*3M91J;(1?4I?Y0#^K(2JZ&3/SP?(EYD._\
ML'N%VBL/3_?FSZ/UMT'8&%4C6]"1AUJ>PA*[/LJ 6^68[F'>G<M[[L114J1U
MCF(HDN@B  7*.ZEE6ARU9@X_Q4-W?Q^]I8KNAT\T/V.CU4?U'8-(CSW%@B9'
MB&V#!^^OWV(%%$>&Q6EJC'0I)CP(('3'C@0R=2=*=3C.+B]+S1F1DE37._<5
M>1;9'3+0>JM7=>K[)T#?N][L==K9:Z+$]BK6M*2"*]C=L"O&KTK5S9+!(1\:
MBJ!/>*9G($$#!R&=US45HP=3>U;4ZN7TF*_[?7R2=G]J;^[#=*^\&Q;G<MMP
M[$UTU^.R"QS:W0,C3'9(+9VO%P:,62BIVJ+UG(I)*>\R947(E'VCP%;4IU<;
MCJ^GYYDW;:4=4<C;9S=JAQS4/_<C=T^X/6/?O4FE]8]_W[3D?L37EU6GHRH/
M8YFSG)U.[5V&AWLB9[&OS =JF_%,#%X I#CZ#E93TT6.1R+4(2BW+.IC#M/3
MO[GKK3K6T=@[%V??VVK:M@G-YLD1 ;0I-^D K<.W-(2TBI3IBA,FE@81D>F=
M=RW(<ZHH$,8A#<>F$_[BK<9?+[_\R4K#EIQ]OB; ?A1\D\YY*.KDI=MAQ,3"
M[IU/:B:]VBE74#M*Y/N5XIM-5V[0S!19PI%H6:+7-\S3WG3;O&RP)C\0D -[
M=;BKU,;D';=&=MYG>\6T.CG5NL6'1Z=>:[CW;N&F:'U_;+DBDO2]>R-S)(N'
MMZL*3@?LG"<''Q9_@3<@9L"JGRJE.1(R9Y>$:B$=3\D8U$\5WD=;U]*]P/FQ
M[)N-YBP1E#IS5.JTEH20GQ3(\&.3HY5A(E4#N1^--0J2AQ;\&^ >?CRB34JM
MO5^OXEE*U7Z<"7WJBT[0,-%4=GW%E]6SW8!HV?-;O,Z<;RS2CRPH/UTHB3:M
MIALS60DWT41)1Z1%)%J1R8P(D*0 #-,_>4FX+Z:T(Y.R_8C=U4\T_CJZY5K8
M<U"Z1V9I'L-;MA:^9 R)$7"?@*]:#P+Z;5,T._<?HJL8@HV3*L1,B@";@1$<
MGJEXA1;BY=$34!_#^&0EBBE2%CQ5;]W1N7L=Y:*KM+8]CO-<TIW<E]?:HAYU
M9LJTH=)092YTJU E;M6YTHU-1 @@505#?E#UQFB\H.%*]4>/\Z.W>P&MJ/TH
MJ?7S>=VZ_P ]O;NEKK2EEO-#".5F$*Q=HB<8+B+64;.&KTC!X9)T5$PI@HHB
M4!, <XK18&EJ$9ZF^B.OEO%GY%V<>[=U/S@=H5K*V1.O!H6O5&N'=;6DTBB=
MHC.-V;P7"L8JL %6 A3C[!'\AOH-L:TJZE5*WUCA[R]7B [J[L[4ZYWWJSM$
MQ@R=G>G.[IS06X+!56R3*LW=W%"Y"'N,>Q;%391[J3!@Y3<HH%31$Z!52)I
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M;+GX(DJ8##Z!QD_%>WP*/3TJ3/Y5^61 P!@# & , 8!\9DBF'D>>?;[>>?\
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M50 <8(2H,$E.,5(<4RN"5@4XR:D:45R"1@# :J4 .,$)4*B'. U4 '&"4J#
M& , 8 P!@ 0YP0U4IP'\O].34C2O,J <9!9*@P!@# & , 8 P!@%!#G!#297
M!*5,!@# & , ?7 :J #C!"5!@D8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
E@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
